Septerna reports Q3 2026 results, SEP-204 named lead TSHR candidate
Phase 1 data for hypoparathyroidism candidate SEP-479 are expected in Q1 2027, the same quarter Septerna plans to start a Phase 1 trial of new candidate SEP-204.
Septerna, Inc. reported third quarter 2026 financial results on November 9, 2026 alongside updates on its clinical pipeline.
The company's Phase 1 single-ascending dose and multiple-ascending dose trial of SEP-479, an oral PTH1R agonist for hypoparathyroidism, is continuing in healthy volunteers, and data are expected in the first quarter of 2027.1
At the American Thyroid Association annual meeting held the prior week, Septerna named SEP-204 as its oral TSHR negative allosteric modulator development candidate, aimed at Graves' disease and thyroid eye disease.1 In preclinical work, SEP-204 inhibited TSHR selectively, normalized T4 thyroid hormone levels and reduced thyroid enlargement and eye bulging in Graves' disease animal models; it was well tolerated in 28-day GLP toxicology studies and its pharmacokinetics support once-daily dosing.1 Assuming remaining preclinical work is completed, the company expects to begin a Phase 1 trial of SEP-204 in healthy volunteers in the first quarter of 2027.1
For SEP-631, a candidate for mast cell-driven diseases, following positive Phase 1 results reported in March 2026, Septerna said it continues to evaluate capital-efficient, signal-finding clinical studies.1
On the partnered side, under its global collaboration with Novo Nordisk that started in July 2025, the companies are advancing oral small molecule programs for obesity, type 2 diabetes and other cardiometabolic diseases; Novo recently took over a development candidate from Septerna's research team and began IND-enabling toxicology studies; the collaboration has generated $13 million in research milestones to date.1
In August 2026, Septerna named Rajiv Patni, M.D., as Chief Medical Officer, describing him as a physician-scientist with more than 25 years of industry experience.1
On finances, Septerna held $565.2 million in cash, cash equivalents and marketable securities as of September 30, 2026, which it said should fund operations at least into mid-2029.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.